Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,742.00
Bid: 1,742.00
Ask: 1,743.00
Change: -33.00 (-1.86%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 12th Nov 2013 09:20

Accesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation.Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review.Babcock International: Jefferies increases target price from 1250p to 1600p retaining a buy recommendation. Investec places its target price (prev.: 1175p) under review, while keeping its add rating.Balfour Beatty: UBS raises target price from 220p to 245p, while downgrading from neutral to sell.British Sky Broadcasting: Alphavalue shifts target price from 1055.2p to 1056.7p and upgrades from add to buy. Credit Suisse reduces target price from 810p to 700p downgrading to underperform.BTG: Investec places its target price (prev.: 472p) under review, while its buy recommendation is kept.Catlin Group: Canaccord Genuity moves target price from 540p to 550p and maintains a buy recommendation.Central Asia Materials: FinnCap initiates with a target price of 222p and a buy recommendation. Canaccord Genuity takes target price from 210p to 245p and stays with its buy recommendation.Chesnara: Canaccord Genuity moves target price from 290p to 300p, while downgrading from buy to hold.Cobham: Deutsche Bank lowers target price from 275p to 270p and maintains a hold recommendation. JP Morgan cuts target price from 310p to 270p reiterating a neutral rating. UBS lowers target price from 305p to 290p leaving its buy recommendation unchanged.Coca-Cola HBC: Goldman Sachs reduces target price from 2100p to 2000p and retains a neutral rating.Craneware: Investec raises target price from 365p to 530p and maintains a buy recommendation.Cropper (James): Westhouse Securities increases target price from 350p to 450p, while downgrading to add.F&C Asset Management: Barclays initiates with a target price of 90p and an underweight rating.GlaxoSmithKline: Panmure Gordon reduces target price from 1850p to 1750p and downgrades from buy to hold.Halfords Group: Deutsche Bank raises target price from 330p to 410p, but still recommends selling.Hunting: FinnCap cuts target price from 900p to 840p, while its hold recommendation is kept.Inmarsat: Alphavalue shifts target price from 729.7p to 732.6p upgrading from reduce to add.Ithaca Energy: Liberum Capital moves target price from 210p to 207p, while staying with its buy recommendation.Lonmin: Deutsche Bank increases target price from 315p to 390p and stays with its hold recommendation. Citi ups target price from 420p to 453p and reiterates a buy recommendation. HSBC raises target price from 485p to 512p leaving its overweight rating unaltered. JP Morgan takes target price from 400p to 430p and keeps an overweight rating.Morgan Advanced Materials: Jefferies lowers target price from 345p to 340p staying with its buy recommendation. JP Morgan moves target price from 335p to 330p, while leaving its overweight rating unchanged. Investec reduces target price from 410p to 390p, while its buy recommendation remains unchanged.Rentokil: Jefferies raises target price from 104p to 116p and keeps a hold recommendation.Rightmove: Panmure Gordon takes target price from 3000p to 3130p maintaining a buy recommendation.Royal Bank of Scotland: Nomura ups target price from 270p to 285p maintaining a reduce rating.RSA Insurance Group: Deutsche Bank shifts target price from 117p to 115p and retains a hold recommendation. Nomura lowers target price fromk 120p to 113p reiterating a neutral rating. JP Morgan cuts target price from 140p to 126p and downgrades to neutral.Shire: Societe Generale increases target price from 3270p to 3615p reiterating a buy recommendation.Smith (WH): Deutsche Bank raises target price from 960p to 1075p maintaining a buy recommendation. UBS increases target price from 750p to 1000p.Speedy Hire: Panmure Gordon shifts target price from 73.6p to 75p and stays with its hold recommendation.Synergy Health: Investec moves target price from 1140p to 1165p and reiterates a buy recommendation.Trifast: N+1 Singer ups target price from 68p to 89p and leaves its buy recommendation unchanged. FinnCap takes target price from 66p to 91p retaining a buy recommendation. Westhouse Securities places both its target price (prev.: 80p) and its buy recommendation under review.Vodafone Group: Espirito Santo ups target price from 215p to 230p and retains a neutral rating.Workspace Group: Liberum Capital takes target price from 546p to 584p and maintains a buy recommendation. Investec ups target price from 500p to 560p retaining a buy recommendation.
More News
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.